So here's what's happening with PDS Biotechnology (PDSB) today: the stock is up big, and it's all about some pretty encouraging cancer trial data that just got published. The company announced that clinical and immunological biomarker data from Stage 1 of a Phase 2 trial of their treatment, PDS01ADC, has been published in the Journal of Clinical Oncology (JCO) Oncology Advances. When a biotech company gets data published in a journal like that, investors tend to pay attention.
PDS Biotechnology Stock Jumps on Promising Cancer Trial Data
MarketDash
Shares of PDS Biotechnology surged Wednesday after the company published Phase 2 data showing significantly improved response rates and survival trends in colorectal and prostate cancer studies.
Get PDS Biotechnology Alerts
Weekly insights + SMS alerts
Trial Shows Immune System Gets a Boost
The published data focuses on colorectal cancer patients who, frankly, haven't had much luck with other treatments. The key finding? PDS01ADC appears to significantly enhance the immune response in these patients. The numbers tell the story: the study showed a 78% objective response rate in patients treated with PDS01ADC. For comparison, a parallel trial that didn't use PDS01ADC showed a 35% response rate. That's a meaningful difference.
This data comes from a study of 22 patients. Even more compelling than the response rate might be the survival data. For those treated with PDS01ADC, the two-year survival rate was over 80%. Again, in the parallel group, it was 35%. When you're talking about patients who have failed prior treatments, numbers like that get people excited.
The Clock Is Still Ticking (In a Good Way)
In cancer trials, "progression-free survival" (PFS) is a huge deal. It measures how long patients live without their cancer getting worse. In this trial, the median PFS for the PDS01ADC group wasn't even reached at the minimum follow-up point of 13.1 months. They're still going. In the parallel trial without PDS01ADC, the median PFS was 8.1 months. So not only are more patients responding to the treatment, but the benefit also appears to be lasting longer.
And There's More Good News From a Different Cancer
This wasn't the only piece of positive data PDS Biotech had to share. Earlier, the company presented early results from a separate trial led by the National Cancer Institute (NCI) that's looking at PDS01ADC for prostate cancer. This data was presented at an American Association for Cancer Research (AACR) special conference.
This study involved patients with metastatic castration-resistant prostate cancer, most of whom were on their third line of treatment—so again, a tough group to treat. The combination of PDS01ADC and the chemotherapy drug docetaxel showed a median progression-free survival of 9.6 months. It also showed a median decline in prostate-specific antigen (PSA, a key biomarker for prostate cancer) of 40%. Even better, 6 out of 16 patients saw their PSA decline by more than 50%.
PDSB Stock Price Activity: All this news translated directly to the stock price. PDS Biotechnology shares were up 25.47%, trading at $1.33 at the time of publication on Wednesday.
More News
Trump Says Strait Is 'Permanently' Open. Tanker Data Says: Not So Fast.
Make This One Trade at 2:59 PM on Friday Afternoon, and you'll Thank Me Monday Morning
Trump Doubles Down: Threatens to Fire Powell If He Doesn't Leave, Vows Fed Building Probe Will Continue
Tech Stocks Rally While Dow Dips: Markets Navigate Geopolitical Jitters and Strong Earnings
Bank of America's Q1: A $8.6 Billion Nod to a Resilient Economy, With a Side of Caution
Trump's Secret Retirement Fund
Morgan Stanley Turns Market Chaos Into Record Profits
Uber's $10 Billion Robotaxi Bet Sends Stock Soaring
Get PDS Biotechnology Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all newsTrump Says Strait Is 'Permanently' Open. Tanker Data Says: Not So Fast.
By MarketDash
April 15, 2026
Make This One Trade at 2:59 PM on Friday Afternoon, and you'll Thank Me Monday Morning (Ad)
By Timothy Sykes
Trump Doubles Down: Threatens to Fire Powell If He Doesn't Leave, Vows Fed Building Probe Will Continue
By MarketDash
April 15, 2026
Tech Stocks Rally While Dow Dips: Markets Navigate Geopolitical Jitters and Strong Earnings
By MarketDash
April 15, 2026
Bank of America's Q1: A $8.6 Billion Nod to a Resilient Economy, With a Side of Caution
By MarketDash
April 15, 2026
How To Claim Your Pre-IPO Stake In SpaceX! (Ad)
By Paradigm Press
Morgan Stanley Turns Market Chaos Into Record Profits
By MarketDash
April 15, 2026
Uber's $10 Billion Robotaxi Bet Sends Stock Soaring
By MarketDash
April 15, 2026